Merck is in talks to acquire Revolution Medicines in a deal that could value it at around $30 billion, according to people ...

The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

As someone who's followed the evolution of cancer treatments closely—both personally, having supported loved ones through ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ...

Gallbladder cancer is a rare and often aggressive malignancy that develops in the tissues of the gallbladder — a small, ...

The entrepreneur’s cancer institute is striving to be the financial glue for an embattled research community while going ...

Countries like Spain have used 'most-favored-nation' drug pricing for decades. While it may reduce the cost of drugs, it will ...

ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100)The combination demonstrated a favorab ...

Stage 4 RCC is metastatic, with common spread to lungs, bones, liver, brain, and adrenal glands. Understanding IMDC risk is ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company," 6990.HK) today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, ...

SAN FRANCISCO -- Incorporating the recently approved bispecific antibody zanidatamab (Ziihera) into first-line treatment for ...